Erasca Announces Pricing of Underwritten Offering of Common Stock
Summary
SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 15,384,616 shares of its common stock at a price of $6.50 per share. The offering is expected to close on December 13, 2022, subject to the satisfaction of customary closing conditions.Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes.J.P. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We believe our teams capabilities and experience, further guided by our scientific advisory board which includes the worlds leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.Forward Looking StatementsErasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.